Supersets are gaining attention as a time-effici
Author: Michael
Imagine noticing subtle changes in your memory o
Longevity.
Phase 2 study data indicates ‘dose-dependent i
Company aims to inhibit SARM1 enzyme to prevent
A new study highlights how three key blood marke
Have you ever questioned whether even a small di
Longevity.
Designed to protect key retinal cells, company’s Fas inhibitor drugs aim to prevent vision loss in a range of conditions. With the world buzzing about Neuralink’s latest project to restore sight to the blind, others take the view that prevention is better than cure. To that end, US biopharma ONL Therapeutics has completed an oversubscribed $65 million Series D financing round to advance the clinical development of its novel therapeutics aimed at protecting retinal cells. ONL’s approach is focused on inhibiting Fas-mediated cell death, a critical mechanism in many ophthalmic diseases. Fas signaling plays a dual role in activating cell death and…